Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Volrustomig by AstraZeneca for Hepatocellular Carcinoma: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II...
Volrustomig by AstraZeneca for Cervical Cancer: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III...
Volrustomig by AstraZeneca for Non-Small Cell Lung Cancer: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
Volrustomig by AstraZeneca for Hypopharyngeal Cancer: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Hypopharyngeal Cancer. According to GlobalData, Phase III...
Volrustomig by AstraZeneca for Laryngeal Cancer: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Laryngeal Cancer. According to GlobalData, Phase III...
Volrustomig by AstraZeneca for Oropharyngeal Cancer: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III...
Volrustomig by AstraZeneca for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Volrustomig by AstraZeneca for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Head And Neck Squamous Cell Carcinoma (HNSC)....
Volrustomig by AstraZeneca for Rhabdomyosarcoma: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I drugs...
Volrustomig by AstraZeneca for Leiomyosarcoma: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase I drugs...
Volrustomig by AstraZeneca for Pleomorphic Liposarcoma: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase I for Pleomorphic Liposarcoma. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Volrustomig?
Volrustomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Cervical Cancer. According to Globaldata,...
Volrustomig by AstraZeneca for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to...
Volrustomig by AstraZeneca for Malignant Pleural Mesothelioma: Likelihood of Approval
Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Malignant Pleural Mesothelioma. According to GlobalData, Phase...